A clinical trial for drug fosigotifator in ALS patients failed to meet its primary endpoint, with no marked effect on disease progression, according to results from the Healey ALS platform trial. Produced by Calico Life Sciences with AbbVie, it showed no significant improvement in secondary endpoints either. However, slower deterioration in muscle strength was observed. Fosigotifator continues to be studied for other diseases.
Understanding the Ethics of AI in ABA Therapy
Artificial intelligence (AI) is being increasingly used in healthcare, including in applied behaviour analysis (ABA). AI’s potential includes analysing complex behavioural patterns and supporting decision-making
